Talk:Ancillary testing in prostate cancer

From Libre Pathology

Revision as of 15:20, 1 November 2022 by Michael (talk | contribs)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Jump to navigation Jump to search

MSI testing - in BRCA1/2: Barata P, Agarwal N, Nussenzveig R, Gerendash B, Jaeger E, Hatton W, Ledet E, Lewis B, Layton J, Babiker H, Bryce A, Garje R, Stein C, Kiedrowski L, Saylor P, Sartor O (August 2020). "Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA". J Immunother Cancer 8 (2). doi:10.1136/jitc-2020-001065. PMC 7422632. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7422632/.

Retrieved from "https://librepathology.org/w/index.php?title=Talk:Ancillary_testing_in_prostate_cancer&oldid=52201"